Baltic Atherosclerosis Conference 2021

03.12.2021 - 04.12.2021 Tallinn, Estonia

Personal prevention of CV diseases

Mikk Jürisson (Estonia)

Associate Professor of Public Health, Institute of Family Medicine and Public Health

Biography: Graduated from the Faculty of Medicine, University of Tartu; residency in child neurology at the University of Tartu, Postgraduate Diploma in Public Health at the London School of Hygiene and Tropical Medicine, a doctoral degree at the University of Tartu. Currently an Assistant Professor in Public Health, University of Tartu. Major areas of interest: epidemiology and public health, COVID-19 active surveillance study in Estonia, clinical studies in personalized prevention of CVD, health technology assessments.

Small Hall

Media:

view the video of this presentation

Synopsis: Estonia is a country with one of the highest CVD event rates in Europe and prevalence of cardiovascular disease risk factors is high. For optimal management decisions in primary prevention, accurate estimation of an individual’s atherosclerotic cardiovascular disease risk is needed. There is currently only limited evidence for the high polygenic risk score (PRS)-based proactive prevention effect on cardiovascular disease (CVD) risk reduction. Risk captured by PRS appears largely independent of traditional risk factors and can be identified before the development of traditional clinical risk factors. Genetic risk is modifiable through lifestyle modifications and medications. However, further work is needed before PRS can be implemented clinically.
We have performed a randomised controlled study on CV risk factor intervention in middle-age subjects with very high CVD PRS. The study was assessing the impact of a proactive high PRS- based prevention strategy on CVD risk factors over 12 months. We used the Kardiokompassi tool, which comprehensively utilises the genetic profile of a subject in combination with conventional health information to assess the risk for CVD. The Kardiokompassi risk calculator combines traditional health information with genome information to evaluate the risk of cardiac disease more precisely, motivating users to make better lifestyle choices.
The results of the study will be presented.

This agenda item is presented in the following session: S2 - Early atherosclerosis, hypertension and personalised prevention

Plenary session

03.12.2021 11:45 - 13:15